Ameriprise
MLTX icon

Ameriprise’s MoonLake Immunotherapeutics MLTX Stock Holding History

Ameriprise’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-130,964
Closed -$1.73M – 4167
2025
Q4 		$1.73M Buy
130,964
+129,122
+7,010% +$1.52M ﹤0.01% 3072
2025
Q3 		$13.2K Sell
1,842
-198,479
-99% -$10.3M ﹤0.01% 4046
2025
Q2 		$9.46M Sell
200,321
-1,200
-0.6% -$48.9K ﹤0.01% 1858
2025
Q1 		$7.87M Sell
201,521
-2,852
-1% -$123K ﹤0.01% 1947
2024
Q4 		$11.1M Buy
204,373
+45,113
+28% +$2.3M ﹤0.01% 1718
2024
Q3 		$8.03M Buy
+159,260
New +$7.46M ﹤0.01% 1992
2023
Q4 		– Sell
-86,862
Closed -$4.95M – 3949
2023
Q3 		$4.95M Buy
+86,862
New +$4.8M ﹤0.01% 2301

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameriprise's MLTX Position: Q1 2026 in Review

Ameriprise sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2026, closing a stake of 130,964 shares — an estimated $1.73M sold.

Ameriprise first reported a position in MLTX in Q3 2023 and held it in 7 quarters. The position peaked at $11.1M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Ameriprise reported no remaining MoonLake Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 130,964 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $1.73M.
  • Ameriprise first reported a position in MoonLake Immunotherapeutics in Q3 2023 and held it in 7 quarters.
  • Ameriprise's MoonLake Immunotherapeutics position peaked at $11.1M in Q4 2024.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.